Drug Type Nanobody |
Synonyms 3-2A2-4 |
Target |
Action- |
Mechanism SARS-CoV-2 S protein neutralization |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| COVID-19 | Preclinical | China | 27 Dec 2022 | |
| COVID-19 | Preclinical | China | 27 Dec 2022 | |
| COVID-19 | Preclinical | China | 27 Dec 2022 |






